CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, a Melphalan injection for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company also develops CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with hematological malignancies; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Frequently asked questions
What sector does CASI Pharmaceuticals, Inc. (CASIF) operate in?
CASI Pharmaceuticals, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is CASI Pharmaceuticals, Inc. (CASIF) current stock price?
As of the latest data, CASI Pharmaceuticals, Inc. stock price is $0.10, with a previous close of $0.10.
What is CASI Pharmaceuticals, Inc. (CASIF) current market capitalization?
CASI Pharmaceuticals, Inc. market cap is approximately 2.06 million.
What is CASI Pharmaceuticals, Inc. (CASIF) Earnings Per Share (EPS)?
The trailing EPS is -$2.00, and the forward EPS is -$1.39.
What is CASI Pharmaceuticals, Inc. (CASIF) EBITDA?
CASI Pharmaceuticals, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.90 million.
Does CASI Pharmaceuticals, Inc. (CASIF) pay dividends?
No. CASI Pharmaceuticals, Inc. does not pay a dividend.
What is CASI Pharmaceuticals, Inc. (CASIF) beta (volatility) score?
CASI Pharmaceuticals, Inc. has a beta of 1.339, suggesting it is more volatile than the market.
